Through a strategic investment in BioHorizons, Henry Schein aims to strengthen its presence in the growing dental implant market. (Photo: Pressmaster/Shutterstock)
2014-1-7 | Business Americas

MELVILLE, N.Y., USA: Henry Schein, one of the largest providers of health care products and services to dental practitioners worldwide, has announced the completion of a 60 percent equity investment in dental implant specialist BioHorizons. Through the investment, the company hopes to gain a stronger presence in two of the world's largest markets for dental implants.

Together with the company's investment in European manufacturer of dental implants CAMLOG Biotechnologies, the agreement with BioHorizons, which was first announced in November last year, will allow Henry Schein to expand its business in the U.S. and German implant markets in particular. In addition, the current investment will help strengthen the company's position and portfolio in the biologics market.

"With the completion of this strategic investment in BioHorizons, we have advanced our dental specialties markets business strategy," said Henry Schein CEO Stanley M. Bergman. "Implant dentistry is a critical element of the profession's transition to digital dentistry, and customer demand for implants and the associated materials is expected to increase as digital processes are adopted and the patient's dental experience is enhanced."